Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience

Bone Marrow Transplantation volume 46, pages 105–109 (2011)Cite this article

Subjects

Abstract

We investigated the feasibility of i.v. BU, CY and etoposide (BUCYE), followed by auto-SCT (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The planned treatment consisted of induction chemotherapy with five cycles of high-dose MTX and two cycles of high-dose cytarabine followed by conditioning with BUCYE (BU 3.2 mg/m2, day −7 to day −5; CY 50 mg/kg, day −3 to day −2 and etoposide 200 mg/m2, twice a day, days −5 and −4) and then ASCT. Between May 2005 and November 2008, 11 consecutive PCNSL patients were treated. All patients completed the treatment as planned, with no cases of treatment-related death or veno-occlusive disease. After BUCYE and ASCT, 10 patients achieved complete response (CR) or unconfirmed CR (CRu). Two patients, one partial response and one CRu, received further whole-brain radiotherapy, with all achieving CR. At a median follow-up of 25.0 months (8.8–50.7 months), six patients had relapsed, with a median event-free interval of 15.0 months (95% confidence interval, 4.5–25.6 months). Median survival time was not reached yet with a 2-year survival rate of 88.9%. The current treatment was feasible with a favorable tolerance profile. However, further regimen optimization is necessary because of high relapse rate.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Abrey LE, DeAngelis LM, Yahalom J . Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859–863.

    Article  CAS  Google Scholar 

  2. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ . Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 20: 4643–4648.

    Article  Google Scholar 

  3. Brevet M, Garidi R, Gruson B, Royer B, Vaida I, Damaj G . First-line autologous stem cell transplantation in primary CNS lymphoma. Eur J Haematol 2005; 75: 288–292.

    Article  CAS  Google Scholar 

  4. Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006; 38: 417–420.

    Article  CAS  Google Scholar 

  5. Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003; 21: 4151–4156.

    Article  CAS  Google Scholar 

  6. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24: 3865–3870.

    Article  CAS  Google Scholar 

  7. Illerhaus G, Muller F, Feuerhake F, Schafer AO, Ostertag C, Finke J . High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008; 93: 147–148.

    Article  CAS  Google Scholar 

  8. Montemurro M, Kiefer T, Schuler F, Al-Ali HK, Wolf HH, Herbst R et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007; 18: 665–671.

    Article  CAS  Google Scholar 

  9. Cheng T, Forsyth P, Chaudhry A, Morris D, Gluck S, Russell JA et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003; 31: 679–685.

    Article  CAS  Google Scholar 

  10. Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol 2008; 26: 2512–2518.

    Article  Google Scholar 

  11. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001; 19: 742–749.

    Article  CAS  Google Scholar 

  12. Kroger N, Hoffknecht M, Hanel M, Kruger W, Zeller W, Stockschlader M et al. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Bone Marrow Transplant 1998; 21: 1171–1175.

    Article  CAS  Google Scholar 

  13. Hanel M, Kroger N, Sonnenberg S, Bornhauser M, Kruger W, Kroschinsky F et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 2002; 81: 96–102.

    Article  CAS  Google Scholar 

  14. Aggarwal C, Gupta S, Vaughan WP, Saylors GB, Salzman DE, Katz RO et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006; 12: 770–777.

    Article  CAS  Google Scholar 

  15. Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen SW et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 25: 1243–1248.

    Article  CAS  Google Scholar 

  16. Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2007; 40: 919–924.

    Article  CAS  Google Scholar 

  17. Postmus PE, Holthuis JJ, Haaxma-Reiche H, Mulder NH, Vencken LM, van Oort WJ et al. Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration. J Clin Oncol 1984; 2: 215–220.

    Article  CAS  Google Scholar 

  18. Kohara H, Ueoka H, Tabata M, Shinagawa K, Hayashi K, Harada M . High-dose etoposide treatment for CNS involvement in a patient with primary non-Hodgkin's lymphoma of the breast. Intern Med 1997; 36: 738–741.

    Article  CAS  Google Scholar 

  19. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer. WHO: Geneva, 2008.

    Google Scholar 

  20. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21: 266–272.

    Article  Google Scholar 

  21. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034–5043.

    Article  Google Scholar 

  22. Creaven PJ . The clinical pharmacology of VM26 and VP16-213. A brief overview. Cancer Chemother Pharmacol 1982; 7: 133–140.

    Article  CAS  Google Scholar 

  23. Ferreri AJ, Crocchiolo R, Assanelli A, Govi S, Reni M . High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk Lymphoma 2008; 49: 2042–2047.

    Article  CAS  Google Scholar 

  24. Morris PG, Abrey LE . Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009; 8: 581–592.

    Article  CAS  Google Scholar 

  25. Yang SH, Lee KS, Kim IS, Hong JT, Sung JH, Son BC et al. Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant. J Neurooncol 2009; 92: 65–71.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the nurses in the oncology wards and house staff members of the Department of Internal Medicine at Asan Medical Center for their dedication and excellent patient care.

Author information

Authors and Affiliations

  1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    D H Yoon, D H Lee, D R Choi, B S Sohn, S Kim, S W Kim, J S Lee & C Suh

  2. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    S W Lee

  3. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    J Huh

Authors
  1. D H Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D H Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D R Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B S Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S W Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J S Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S W Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Huh
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Suh.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoon, D., Lee, D., Choi, D. et al. Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. Bone Marrow Transplant 46, 105–109 (2011). https://doi.org/10.1038/bmt.2010.71

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.71

Keywords

Search

Advanced search

Quick links